Tech Company Financing Transactions
Antheia Funding Round
ATHOS KG and Global Health Investment Corporation participated in a $24 million Series C funding round for Antheia. The round was announced by the company on 1/27/2026.
Transaction Overview
Company Name
Announced On
1/27/2026
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Series C
Investors
ATHOS KG (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand its commercial manufacturing capacity, advance its pipeline of late-stage biosynthetic pharmaceutical ingredients to market, and establish its U.S. manufacturing operations to support national onshoring priorities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1430 O'Brien Dr. A
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
Antheia combines founding intellectual property with world-leading expertise in synthetic biology, informatics, and fermentation technology to provide a stable and cost-competitive supply of plant-based medicines and to transform the discovery, manufacture, and distribution of medicines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christina Smolke
Chief Scientific Officer
Kristy Hawkins
VP - Bus. Development
Yen-Hsiang Wang
Browse more venture capital transactions:
Prev: 1/26/2026: Aviwell venture capital transaction
Next: 1/27/2026: Raylo venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs